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Abstract
The world is currently experiencing an obesity epidemic as declared by the World Health Organization. The traditional view is that
behaviour leading to overeating and under-activity is the major contributing factor for this worldwide epidemic. However, several microbes
are linked to obesity in animals and humans. On the one hand, various microbes, including animal and human viruses, bacteria, parasites and
scrapie agents, increase adiposity in several animal models. Some of these microbes show an association with human obesity, but conclusive
evidence for a causative role of microbes in human obesity is lacking. On the other hand, obese individuals show an altered response to
infections. Obesity is often associated with impaired immune function, which may lead to increased susceptibility to infection with a number
of different pathogens. Hence, certain microbes appear to induce obesity, whereas, obesity itself may exacerbate certain other infections.
Linking the two phenomenon is the immunological property of adipocytes and their progenitors. For instance, proliferating pre-adipocytes
share embryonic origin with immune cells and exhibit phagocytic activity. Taken together it appears that there is a close interrelationship
between adipose tissue, inﬂammatory response, immune system and infections. Hence, it is conceivable that in response to certain
infections, adipose tissue expands similar to the expansion of cells of the immune system. The impaired immune function of adipose tissue in
obesity may exacerbate infections. Considering the global obesity epidemic, it is necessary to further investigate both phenomena.
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Introduction
The World Health Organization considers obesity a global
epidemic (http://www.who.int/nutrition/topics/obesity/en/).
Yet, a link of this epidemic to microbes and infections has
not been carefully explored. While obesity is traditionally
considered a non-communicable disease, increasing evidence
indicates various ways in which obesity and microbes may
interact. Excessive adiposity—the hallmark of obesity, is
associated with several serious chronic diseases, including
diabetes, cardiovascular diseases and cancer. Therefore, it is
imperative to comprehensively understand the effectors and
affecters of adipose tissue. Among other interactions, research
has uncovered dynamic interactions between adipose tissue
and various microbes. These interactions could be classiﬁed as
(i) the effect of microbes on adipose tissue expansion, (ii) the
effect of adipose tissue expansion on microbial infection, and
(iii) the role of adipose tissue in immune response. This review
presents a synthesis of the microbe–adipose tissue inter-
actions, and suggests novel directions for future research.
The Effect of Microbes on Adipose Tissue
Expansion
The aetiology of obesity is multifactorial. In addition to the
commonly considered contributors to obesity (overeating and
under-exercising), additional factors such as genetic inheri-
tance, endocrine alterations, sleep disturbances and many
other putative factors may play a role, including certain
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microbes [1]. Studies from several laboratories over the past
30 years have indicated that certain infections might promote
development of obesity—termed as ‘Infectobesity’[2]. Induc-
tion of obesity in mice experimentally infected with canine
distemper virus was the ﬁrst report of Infectobesity [3]. Since
then, several animal and human viruses, bacteria, parasites and
scrapie agents have been reported to cause obesity in models
using insects, chickens, rodents and non-human primates [4].
The bacterial endotoxin alone can induce adipose tissue
expansion [5]. Several additional microbes including Chlamydia
pneumoniae [6], Selenomonas noxia [7], Helicobacter pylori [8],
the gut microﬂora [9], and collective load of infection with
herpes simplex virus 1 or 2, enterovirus and C. pneumoniae
[10] are associated with human obesity. The mechanism
underlying the adipogenic action of these microbes varies,
ranging from an effect on the central nervous system (canine
distemper virus, Borna disease virus), to metabolism
(gut microbiota) and adipose tissue (adenoviruses) [4]. Ade-
noviruses are the only human pathogens that are causatively
and correlatively linked with animal and human obesity,
respectively, and seem to directly inﬂuence the adipose tissue.
Therefore, adipogenic adenoviruses offer an excellent example
to understand microbe–adipose tissue interaction, as discussed
below in detail.
Adenoviruses are a family of icosahedral, non-enveloped,
double-stranded DNA viruses with diameters ranging from 65
to 80 nm. Human adenoviruses are a group of over 50
subtypes, divided into subgroups A to F based on their
sequence similarity and haemagglutination properties. Typically
they are linked to infections involving the upper or lower
respiratory tract, the gastrointestinal tract, or the conjunctiva,
but some rare manifestations include haemorrhagic cystitis,
hepatitis, haemorrhagic colitis, pancreatitis, nephritis and
encephalitis [11]. Adenovirus infections are common in young
children, but latent infections may persist or recur over a
lifetime. Globally, the prevalence of adenovirus infections is
widespread [12,13]. The adipogenic potential of all adenovi-
ruses is not known.
SMAM-1, an avian adenovirus, was the ﬁrst adipogenic
adenovirus identiﬁed. Experimental infection of chickens by
SMAM-1 increased adiposity, yet reduced serum cholesterol
and triglyceride levels compared with uninfected controls
[14,15]. Uninfected chickens placed in the cages of experi-
mentally infected chickens also acquired SMAM-1 infection and
increased adiposity. A study screened a small group of humans
for the presence of SMAM-1 antibodies as an indicator of past
SMAM-1 infection [16]. Twenty per cent of the humans were
seropositive for SMAM-1, -a particularly surprising ﬁnding
considering that conventionally, humans are not considered
susceptible to avian adenovirus infection. Moreover, the
SMAM-1 seropositive subjects had signiﬁcantly greater body
mass index (an indicator of adiposity), but lower serum
cholesterol and triglyceride levels. These similarities in the
ﬁndings between the animal and human studies suggested a
causative role of SMAM-1 in increasing adiposity in humans,
but did not conclusively establish such a role.
Among the human adenoviruses, adenovirus 36 (Ad36) was
the ﬁrst human adipogenic virus reported. Ad36 was ﬁrst
isolated in Germany in the faecal sample of a girl with enteritis
in 1978 [17]. It is antigenically distinct from other human
adenoviruses, which greatly helps in speciﬁcally identifying
neutralizing antibodies in humans. Presence of neutralizing
antibodies to Ad36 indicates current or past infection with the
virus. Several experiments showed that Ad36 increases
adiposity in various animal models including chickens, mice,
rats and marmosets [18–23]. It is remarkable that Ad36 infects
and increases adiposity in all animal models tested. Ad36-
infected rodents show signiﬁcantly greater adiposity just
4 days after inoculation [24], and the adipogenic effect persists
even 6–7 months later [21,22]. The adipogenic effect of Ad36
is evident in chow-fed animals. However, in mice fed a 60% fat
diet, Ad36 could not increase adiposity over that induced by
the high-fat diet [25]. Various experiments show that about
60–100% of the Ad36-infected animals develop obesity,
deﬁned as adiposity >85th centile for that in the uninfected
control group. Also, compared with uninfected control
animals, Ad36-infected animals have about 35–60% greater
adipose tissue mass—a moderate increase. This level of fat gain
is very similar to that increased by many genetic models of
obesity [26–28].
The exact route of transmission of Ad36 in humans is
unclear. When blood obtained from Ad36-infected animals
was inoculated into a fresh set of animals, viral infection and
obesity was transmitted to the recipient animals [19].
Although, intravenous transmission is not a natural route of
infection for Ad36, the experiment demonstrated a Koch’s
postulate and also suggested the possibility of blood-borne
transmission of Ad36 for humans receiving blood transfusions.
Considering that Ad36 was ﬁrst isolated from the faecal
sample of a girl suffering from enteritis, faeco–oral transmis-
sion is a possibility. Animals experimentally infected with Ad36
excrete the virus in faeces [19,22]. Cage mates of Ad36-
inoculated animals acquire Ad36 infection rapidly in as little as
12 h and seem to harbour the viral DNA for several weeks
[19]. In another experiment, Ad36 DNA was present in the
organs of Ad36-infected mice for at least 12 weeks; however,
horizontal transmission by these mice to cage mates was not
possible beyond 8 weeks [29]. Viral DNA shows that Ad36
spreads to multiple organs, including liver, lungs, kidneys,
spleen, heart, adipose tissue and brain [24]. It is unknown if
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Ad36 DNA recovered from the brain tissue was from the
blood vessels in the organ, or if the virus had crossed the
blood–brain barrier. Afﬁnity of Ad36 to adipose tissue seems
peculiar. Ad36 mRNA could be recovered from the adipose
tissue of mice even 5 months after viral inoculation [25]. In
Ad36-infected animals, the amount of viral load in adipose
tissue correlated with the amount of adipose tissue [19], which
suggested that Ad36 may have a direct inﬂuence on the
expansion of adipose tissue depots, and offered directions for
testing the peripheral effect of Ad36 in future experiments.
Although animal experiments convincingly demonstrated
that Ad36 increases adiposity, it is critical to determine the
role of Ad36 in human obesity and in the global epidemic of
obesity. As a consequence of ethical considerations, experi-
mental Ad36 infection of humans is not likely. Instead, a
framework has been proposed to indirectly assess such a role
of Ad36 [2]. One key component of this approach is to test
the hypothesis that humans who are naturally infected with
Ad36 will exhibit a phenotype similar to that observed in
animals that are experimentally infected with Ad36. In Ad36-
infected animals, the major phenotypic changes include greater
adiposity, yet better metabolic proﬁle including lower serum
cholesterol and triglycerides, better glycaemic control and less
hepatic steatosis [4,21,23,25]. Interestingly, natural Ad36
infection appears to mirror associations with these phenotypes
in humans. Nearly a dozen studies from Korea [30,31], Italy
[32], and the USA [2] have reported the association of Ad36
with overweight and/or obesity in adults and children. Two
studies could not ﬁnd such association [33,34]. Twins who
were discordant for Ad36 infection provided strong evidence
for the possible adipogenic role of Ad36 in humans. Twins with
natural Ad36 infection had signiﬁcantly greater body weight
and body fat, compared with their co-twins who were
uninfected [35]. Lower serum lipids were associated with
Ad36 infection in some, but not all, of these studies. A study of
1400 Caucasian, Black or Hispanic men, women or children
from four separate cohorts showed signiﬁcantly better
glycaemic control and lower hepatic fat levels in individuals
who were naturally infected with Ad36 [25]. Natural Ad36
infection was positively associated with obesity and negatively
associated with non-alcoholic fatty liver disease in an Italian
population [32,36,37]. Hence, similar to the phenotype in
Ad36-infected animals, natural Ad36 infection is associated
with obesity and better metabolic proﬁle.
Another aspect of determining the role of Ad36 in human
obesity is to understand the molecular mechanism underlying
the adipogenic effect. Ad36 induces adipogenic commitment,
replication, and differentiation of resident stem cells/stromal
cells from adipose tissue and increases lipid accumulation in
these cells [38–41]. The adipogenic effect of Ad36 is also
evident in adipose tissue of Ad36-infected animals. Visceral
adipose tissue of Ad36-infected rats had 3- to 60-fold greater
expression of genes of adipogenic cascade, compared with that
in uninfected rats, that were matched for body fat [21]. Hence,
Ad36 appears to contribute to increased adiposity by increas-
ing fat cell number and size—a hypothesis that was indirectly
tested in humans. A study showed that the potential of
adipocyte progenitors to differentiate into adipocytes was
about eight-fold greater in Pima Indian subjects who harboured
Ad36 DNA in their adipose tissue, compared with their
counterparts without the viral DNA [41]. This indicated an
association of Ad36 infection with greater adipogenic potential
in humans.
Associations do not establish causations. However, three
aspects particularly strengthen the possibility of a causative
role for Ad36 in a subgroup of human obesity. (i) Obesity is
usually associated with poor metabolic proﬁle. The ability of
Ad36 to increase adiposity but to improve metabolic proﬁle in
animals is paradoxical and unusual. Nonetheless, observation
of this peculiar phenomenon in humans who are naturally
infected with Ad36 argues in support of a causative role for
Ad36. (ii) In addition to the above-cited cross-sectional
associations of natural Ad36 infection in humans, a recent
study reported the ﬁrst longitudinal association. A 10-year
follow-up of over 1400 Hispanic men and women who were
naturally infected with Ad36 showed a signiﬁcant gain in
adiposity and better glycaemic control, compared with
uninfected individuals. (iii) Not all adenoviruses are adipogenic.
The avian adenovirus Chick Embryo Lethal Orphan (or CELO)
virus, and human adenoviruses Ad2 or Ad31 are non-
adipogenic in animal models. Similarly, natural infection of
Ad2 or Ad31 is not associated with obesity. Taken together, it
appears that certain microbes induce adipose tissue expansion
and other related metabolic changes.
The Effect of Adipose Tissue Expansion on
Microbial Infection
The reports presented above indicate that changes in fat mass
and the immune system are intimately linked and certain
microbes may contribute to adipose tissue expansion. Con-
versely, reports also indicate that a state of excess adiposity
can increase the susceptibility to infections in humans and
mice. Many studies demonstrating the negative impact of
excess adiposity on immune function have used mouse models
lacking leptin (ob/ob)—a key adipokine, or the leptin receptor
(db/db). Obese mice are more susceptible to bacterial
infections and pneumonia [42]. Ob/ob mice have impaired
pulmonary clearance upon Klebsiella infection [43], and also
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enhanced lethality and delayed clearance of Streptococcus
pneumonia from the lungs [44], which can be rescued with
intraperitoneal injections of leptin before the infection. Other
studies showed greater pulmonary Mycobacterium tuberculosis
load [45] and delayed clearance of the Mycobacterium abcessus
[46] upon challenge. The db/db mice lacking the leptin receptor
are more susceptible to hind paw staphylococcal infection and
display a higher inﬂammatory response compared with wild-
type mice [47]. Furthermore, ob/ob and db/db mice show
impaired resistance to hepatic Listeria monocytogenes infection
[48]. These studies clearly highlight the importance of leptin in
host defence but they do not offer insight into mechanisms by
which excess body fat actually affects host defence. In mice
that have impaired leptin function and are also obese (ob/ob
and db/db), it is hard to attribute the effect to obesity alone.
Diet-induced obesity in rodents closely mimics human
obesity and leads to many comorbidities associated with
obesity. Mice with diet-induced obesity have greater morbidity
and mortality compared with control lean mice during primary
or secondary inﬂuenza infection [49,50], reduced natural killer
cell activity, poor dendritic cell processing and impaired CD8+
T-cell function [50,51]. In this model, it is unclear whether the
observed response to infection should be attributed to
adiposity or the high-fat diet. A thought is to use genetic
obesity models with intact leptin signalling and diet-induced
obesity models in conjunction to understand the impact of diet
versus the state of excess adiposity on immunity [52,53]. In
humans, immune cell dysfunction because of obese conditions
may result in impaired host defence and may be a risk factor
for postoperative nosocomial [54], periodontal [55] and
respiratory infections [56]. Additionally several studies have
reported obesity to be an independent risk factor for
postoperative infections [57–60]. Recently, obesity was
reported as a predictor for a worse outcome of the 2009
inﬂuenza A (H1N1) pandemic strain [61]. A study using
Canada’s cross-sectional population based health surveys
reported that the obese individuals were at a greater risk
for respiratory hospitalization during the seasonal ﬂu periods
[62]. In children, obesity appears to be a confounding factor in
respiratory infections [63]. Overall, these observations indi-
cate that excessive adipose tissue expansion predisposes
individuals to various infections.
The Role of Adipose Tissue in Immune
Response
The interactions between nutrition, nutritional status and
immune function have been investigated. Numerous adipokines
released by mature adipocytes act on immune cells to
modulate innate and adaptive responses [64,65]. Leptin, a
key adipokine, indirectly affects immune responses [66]. In the
obese, such alterations in inﬂammation and immune cell
function play a signiﬁcant role in nearly all pathophysiological
effects of obesity [67,68]. These modulations of the immune
system are often independent of microbial infection, and are
referred to as sterile inﬂammation.
The main function of adipose tissue was once considered
limited to storing the surplus energy. Increasing evidence
strongly indicates endocrine and immune components of
adipose tissue functions. Adipose tissue is comprised of several
cell types, including pre-adipocytes and adipocytes, stromal
vascular cells, cells of the immune system and endothelial cells.
The immune function of adipose tissue may be attributed to
the immune cells it harbours and that of adipogenic cells and
their precursors (stromal vascular cells, pre-adipocytes and
adipocytes). Immature haematopoietic cells are present in
adipose tissue, which would suggest adipose tissue to be a site
for formation and maturation of immune cell precursors [69].
Moreover, immune cells in adipose tissue are bone marrow
derived, and inﬁltrate into adipose tissue [70], where, they may
contribute to angiogenesis, apoptotic cell clearance or remod-
elling of extracellular matrix [71]. In addition, these adipose
tissue-based immune cells may participate in combating
infection. Consistent with this view, in vivo injection of bone
marrow mesenchymal stromal cells, which are the bone
marrow counterpart of pre-adipocytes, signiﬁcantly reduces
mortality and bacteraemia of gram-negative sepsis in mice by
enhancing the phagocytic activity of blood monocytes [72,73].
In addition to the immune cells of adipose tissue, evidence is
emerging that even pre-adipocytes and adipocytes are likely to
interact with invading microbes. Cells from adipose lineage
seem to share embryonic origin with monocyte/macrophage
lineages [74, 75]. In particular, both lineages seem to share
some proteins considered speciﬁc to the other lineage. For
example, mature adipose cells express a membrane-bound
NADPH oxidase similar to that present in phagocytes [76],
and pre-adipocytes and adipocytes secrete numerous inﬂam-
matory cytokines such as tumour necrosis factor a and are
sensitive to lipopolysaccharide activation [77]. Alternatively,
aP2 and peroxisome proliferator-activated receptor c, which
were considered speciﬁc to the adipocyte lineage, are detected
in macrophages [78]. The detection of a marker of monocyte–
macrophage lineage the MOMA-2 antigen on pre-adipocytes
and adipocytes strengthened the suggested link between
adipose tissue and macrophage lineages [79]. In 1999, Cousin
et al. [79] showed that pre-adipocytes from 3T3-L1 cells
(mouse embryonic ﬁbroblasts) as well as primary pre-adipo-
cytes displayed phagocytic and microbicidal activities. This
activity was stimulated under inﬂammatory conditions, but was
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lower than that of macrophages [80]. A follow-up study
showed that the stromal–vascular cells isolated from mouse
white adipose tissue or 3T3-L1 pre-adipocytes, when injected
into the peritoneal cavity of mice acquired macrophage-
speciﬁc antigens and high phagocytic activity [81]. These
results further strengthen the link between adipose tissue and
innate immunity processes [81].
Conjectures
It is intriguing why adipose tissue would exhibit an antimicro-
bial role. Perhaps, this is because subcutaneous adipose tissue
forms a second line of defence against microbial invasion, after
the skin is breached, and intra-abdominal fat may offer defence
against microbes and their toxins around the gastrointestinal
system. The expansion of adipose tissue in response to certain
infections may be an attempt to contain infection, similar to
the activation and expansion of immune cells in response to
microbial invasion.
On the other hand, the reduction in immune response
accompanying obesity may be linked to decreased immune
function of excessively expanded adipose tissue. Although
obesity is associated with greater macrophage inﬁltration of
adipose tissue [70], the number of invariant natural killer T cells
that have antimicrobial properties [82] decreases in adipose
tissue in obesity [83]. Also, the expansion of adipose tissue
depletes pre-adipocytes and other adipogenic precursors [84]
that have antimicrobial properties. This may collectively con-
tribute to reduced immune response in obesity.
Conclusions
Certain infections may promote obesity. Conversely, obesity
may inﬂuence the outcome in response to certain infections.
Both phenomena can have profound implications in individual
and public health. The multi-factorial aetiology of obesity is
largely ignored in current prevention/treatment strategies.
Recognizing microbial infection as a contributory factor of
obesity may lead to the development of vaccines to prevent
such a subtype of obesity. A cause-speciﬁc prevention/
treatment approach may be more successful than the blanket
approach followed currently. On the other hand, the reduced
immunity and increased susceptibility of obese individuals to
infections may be an important concern because of the global
epidemic of obesity. About two-thirds of the adult population
in the USA is overweight or obese. In response to an infectious
disease epidemic such as inﬂuenza, adequate immunization or
response to infection of these overweight/obese individuals
may be suboptimal. These considerations underscore the need
to recognize and further investigate the interaction of adipose
tissue and microbial infections.
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